docetaxel anhydrous has been researched along with bisbenzimidazole in 1 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (bisbenzimidazole) | Trials (bisbenzimidazole) | Recent Studies (post-2010) (bisbenzimidazole) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 1,218 | 2 | 170 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mimata, H; Nomura, T; Nomura, Y; Yamasaki, M | 1 |
1 other study(ies) available for docetaxel anhydrous and bisbenzimidazole
| Article | Year |
|---|---|
Expression of the inhibitors of apoptosis proteins in cisplatin-resistant prostate cancer cells.
Topics: Apoptosis; Baculoviral IAP Repeat-Containing 3 Protein; Bisbenzimidazole; Cell Line, Tumor; Cell Proliferation; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Fluorouracil; Humans; Immunoblotting; Inhibitor of Apoptosis Proteins; Male; Microtubule-Associated Proteins; Neoplasm Proteins; Neuronal Apoptosis-Inhibitory Protein; Paclitaxel; Phenotype; Prostatic Neoplasms; Survivin; Taxoids; Tetrazolium Salts; Time Factors; Ubiquitin-Protein Ligases; X-Linked Inhibitor of Apoptosis Protein | 2005 |